About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: OMED
- Previous Close: $8.96
- 50 Day Moving Average: $8.21
- 200 Day Moving Average: $9.49
- 52-Week Range: $7.41 - $15.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.43
- P/E Growth: 0.00
- Market Cap: $332.34M
- Outstanding Shares: 37,092,000
- Beta: 2.81
- Net Margins: -409.54%
- Return on Equity: -1,307.23%
- Return on Assets: -17.68%
Companies Related to OncoMed Pharmaceuticals:
- Current Ratio: 3.83%
- Quick Ratio: 3.83%
What is OncoMed Pharmaceuticals' stock symbol?
OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."
Where is OncoMed Pharmaceuticals' stock going? Where will OncoMed Pharmaceuticals' stock price be in 2017?
8 brokerages have issued 12 month target prices for OncoMed Pharmaceuticals' stock. Their forecasts range from $13.00 to $40.00. On average, they anticipate OncoMed Pharmaceuticals' stock price to reach $19.88 in the next twelve months.
When will OncoMed Pharmaceuticals announce their earnings?
OncoMed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about OncoMed Pharmaceuticals stock?
Here are some recent quotes from research analysts about OncoMed Pharmaceuticals stock:
According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (1/11/2017)
HC Wainwright analysts commented, "We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak wrote in a note.Related Link: Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial FailMeanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017."We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite the compound failed in pancreatic cancer trial."In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with long-term benefits and free-up OncoMed's resources to pursue new development activities," (9/22/2016)
Who owns OncoMed Pharmaceuticals stock?
OncoMed Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.70%), Franklin Resources Inc. (2.60%), Alyeska Investment Group L.P. (1.86%), Renaissance Technologies LLC (1.27%), State Street Corp (0.92%) and Disciplined Growth Investors Inc. MN (0.88%). Company insiders that own OncoMed Pharmaceuticals stock include Alicia J Hager, Austin Gurney, Jack W Lasersohn, Jakob Dupont, John A Lewicki, Paul J Hastings, Sunil Patel and Timothy Hoey.
Who sold OncoMed Pharmaceuticals stock? Who is selling OncoMed Pharmaceuticals stock?
OncoMed Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Turner Investments LLC, Franklin Resources Inc. and Hodges Capital Management Inc.. Company insiders that have sold OncoMed Pharmaceuticals stock in the last year include John A Lewicki, Paul J Hastings and Timothy Hoey.
Who bought OncoMed Pharmaceuticals stock? Who is buying OncoMed Pharmaceuticals stock?
OncoMed Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, State Street Corp and Disciplined Growth Investors Inc. MN.
How do I buy OncoMed Pharmaceuticals stock?
Shares of OncoMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of OncoMed Pharmaceuticals stock cost?
One share of OncoMed Pharmaceuticals stock can currently be purchased for approximately $8.96.